Evidence map›Paper›PMID 42365564›Full record

ArticleEJNMMI radiopharmacy and chemistry2026

Optimization of [

Ting-Yu Chang, Yu-Hou Yu, Zhen-Fan You, Ping-Chuan Cho, Yuh-Feng Wang, Chun-Yi Wu

Abstract read
In one paragraph

Article in EJNMMI radiopharmacy and chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ting-Yu ChangDepartment of Biomedical Imaging and Radiological Sciences, National Yang Ming Chiao Tung University, No. 155, Sec. 2, Li-Nong St, Beitou, Taipei, 112, Taiwan.
Yu-Hou YuHeron Neutron Medical Co., Ltd., Hsinchu, 302, Taiwan.
Zhen-Fan YouHeron Neutron Medical Co., Ltd., Hsinchu, 302, Taiwan.
Ping-Chuan ChoHeron Neutron Medical Co., Ltd., Hsinchu, 302, Taiwan.
Yuh-Feng WangDepartment of Nuclear Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Chun-Yi WuDepartment of Biomedical Imaging and Radiological Sciences, National Yang Ming Chiao Tung University, No. 155, Sec. 2, Li-Nong St, Beitou, Taipei, 112, Taiwan. chunyiwu@nycu.edu.tw.ORCID http://orcid.org/0000-0002-8217-1692

Funding

National Science and Technology Council 113-2623-E-075-001-NU, 113-2314-B-A49-049-MY3, and 114-2623-E-A49-001-NU
6 · The paper itself

Abstract

background4-Borono-2-[

resultsFollowing manual optimization, the optimized conditions were successfully translated to automated synthesis, resulting in non-decay-corrected radiochemical yields of 2.6% ± 1.3% for the BNBA-based protocol, 0.3% ± 0.1% for the P-02-based protocol, and 3.1% ± 0.0% for the P-03-based protocol, respectively. MicroPET/MR imaging and biodistribution analyses demonstrated the highest tumor uptake for [

conclusionsThese findings provide practical insights into precursor design, radiosynthesis optimization, and imaging performance, offering a rational framework to guide future development and clinical translation of [

Indexed as

[18F]FBPAAlditol conjugationBoron neutron capture therapy (BNCT)Nucleophilic substitution reaction

Identifiers

PMID42365564
PMCPMC13582673

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.